My Cart

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF)

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
HLF-H52E5
Human
HEK293
Unconjugated Human HLA-A*24:02&B2M&EBV BRLF1 (TYPVLEEMF) Complex Protein (Monomer, MALS verified) Add to Cart
Total: 1
  • 1

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Background

This is a recombinant protein complex of HLA-A*24:02 presenting an immunodominant 9-mer peptide (TYPVLEEMF) derived from the Epstein-Barr virus (EBV) immediate-early transactivator BRLF1. HLA-A*24:02 is a common class I allele, and this peptide is a well-characterized target for CD8⁺ T cells in EBV-seropositive individuals, making the complex a valuable tool for studying antigen-specific T cell responses in viral immunity and immunotherapies.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CHM-2101CDH17-CAR T; CHM-2101; CHM2101; CHM-2101 CAR-T cellsPhase 2 ClinicalUniversity Of PennsylvaniaStomach Neoplasms; Pancreatic Neoplasms; Neuroendocrine Tumors; Colorectal Neoplasms; Gastrointestinal Neoplasms
Details
BI-905711BI-905711Phase 1 ClinicalBoehringer Ingelheim GmbhPancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms
Details
ARB-202ARB-202Phase 1 ClinicalArbele CorpLiver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms
Details
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland